BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Given Consensus Rating of “Hold” by Brokerages

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) has been given an average rating of “Hold” by the four research firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and two have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $11.00.

Several equities research analysts recently commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of BioXcel Therapeutics in a report on Friday, July 17th. Wall Street Zen lowered BioXcel Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Diversify Wealth Management LLC acquired a new position in BioXcel Therapeutics during the second quarter worth about $27,000. HRT Financial LP acquired a new stake in BioXcel Therapeutics in the 4th quarter valued at about $28,000. XTX Topco Ltd bought a new position in shares of BioXcel Therapeutics during the 2nd quarter valued at about $42,000. Goldman Sachs Group Inc. bought a new position in shares of BioXcel Therapeutics during the 1st quarter valued at about $50,000. Finally, Geode Capital Management LLC grew its stake in shares of BioXcel Therapeutics by 27.7% in the 2nd quarter. Geode Capital Management LLC now owns 28,182 shares of the company’s stock worth $51,000 after purchasing an additional 6,120 shares during the last quarter. Institutional investors own 30.68% of the company’s stock.

BioXcel Therapeutics Trading Up 8.6%

BTAI stock opened at $0.90 on Monday. The firm’s 50-day moving average is $1.05 and its two-hundred day moving average is $1.28. The company has a market capitalization of $27.84 million, a price-to-earnings ratio of -0.16 and a beta of 0.31. BioXcel Therapeutics has a 52 week low of $0.74 and a 52 week high of $8.08.

BioXcel Therapeutics (NASDAQ:BTAI) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.01). The firm had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.38 million. On average, equities research analysts predict that BioXcel Therapeutics will post -2.07 earnings per share for the current year.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.

BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.